Darzalex (daratumumab)

News alerts, weekly reports and conference planners

Company:

Genmab, J&J

Drug class:

CD38 inhibitor

Related drugs:

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab + pomalidomide Sensitive: A1 - Approval daratumumab + pomalidomide Sensitive : A1	daratumumab + pomalidomide Sensitive: A1 - Approval daratumumab + pomalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab Sensitive: A1 - Approval daratumumab Sensitive : A1	daratumumab Sensitive: A1 - Approval daratumumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab + thalidomide Sensitive: A1 - Approval daratumumab + thalidomide Sensitive : A1	daratumumab + thalidomide Sensitive: A1 - Approval daratumumab + thalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	selinexor + daratumumab Sensitive: A2 - Guideline selinexor + daratumumab Sensitive : A2	selinexor + daratumumab Sensitive: A2 - Guideline selinexor + daratumumab Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	daratumumab Sensitive: A2 - Guideline daratumumab Sensitive : A2	daratumumab Sensitive: A2 - Guideline daratumumab Sensitive : A2
CD38 expression	Multiple Myeloma	CD38 expression	Multiple Myeloma	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B	daratumumab Sensitive: B - Late Trials daratumumab Sensitive : B
PTPRC expression	Multiple Myeloma	PTPRC expression	Multiple Myeloma	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
CD200 expression	Multiple Myeloma	CD200 expression	Multiple Myeloma	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
CD27 expression	Multiple Myeloma	CD27 expression	Multiple Myeloma	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
CD38 overexpression	Multiple Myeloma	CD38 overexpression	Multiple Myeloma	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
CD38 expression	Waldenstrom Macroglobulinemia	CD38 expression	Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
CD20 expression	Lymphoma	CD20 expression	Lymphoma	daratumumab + NKTR-255 Sensitive: C3 – Early Trials daratumumab + NKTR-255 Sensitive : C3	daratumumab + NKTR-255 Sensitive: C3 – Early Trials daratumumab + NKTR-255 Sensitive : C3
CD38 expression	Lymphoma	CD38 expression	Lymphoma	daratumumab + NKTR-255 Sensitive: C3 – Early Trials daratumumab + NKTR-255 Sensitive : C3	daratumumab + NKTR-255 Sensitive: C3 – Early Trials daratumumab + NKTR-255 Sensitive : C3
CD38 positive	Multiple Myeloma	CD38 positive	Multiple Myeloma	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax + daratumumab Sensitive: C3 – Early Trials venetoclax + daratumumab Sensitive : C3	venetoclax + daratumumab Sensitive: C3 – Early Trials venetoclax + daratumumab Sensitive : C3
FADD underexpression + BID underexpression	Multiple Myeloma	FADD underexpression + BID underexpression	Multiple Myeloma	daratumumab Resistant: C3 – Early Trials daratumumab Resistant : C3	daratumumab Resistant: C3 – Early Trials daratumumab Resistant : C3
Chr del(17p)	Leukemia	Chr del(17p)	Leukemia	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3	daratumumab Sensitive: C3 – Early Trials daratumumab Sensitive : C3
KRAS mutation	Multiple Myeloma	KRAS mutation	Multiple Myeloma	trametinib + daratumumab + pomalidomide Sensitive: C4 – Case Studies trametinib + daratumumab + pomalidomide Sensitive : C4	trametinib + daratumumab + pomalidomide Sensitive: C4 – Case Studies trametinib + daratumumab + pomalidomide Sensitive : C4
CD19 negative + CD20 negative + CD22 negative	B Acute Lymphoblastic Leukemia	CD19 negative + CD20 negative + CD22 negative	B Acute Lymphoblastic Leukemia	venetoclax + daratumumab Sensitive: C4 – Case Studies venetoclax + daratumumab Sensitive : C4	venetoclax + daratumumab Sensitive: C4 – Case Studies venetoclax + daratumumab Sensitive : C4
Chr t(11;14) + BCL2 overexpression	Multiple Myeloma	Chr t(11;14) + BCL2 overexpression	Multiple Myeloma	venetoclax + daratumumab Sensitive: D – Preclinical venetoclax + daratumumab Sensitive : D	venetoclax + daratumumab Sensitive: D – Preclinical venetoclax + daratumumab Sensitive : D

Darzalex (daratumumab)

Associations
(26)

Associations
(26)

Darzalex (daratumumab)

Associations(26)

Associations(26)

Associations
(26)

Associations
(26)